share_log
Moomoo 24/7 ·  Apr 10 07:06
BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment